- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 11
The Center for Biosimilars® recaps the top stories for the week of November 11, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 11, 2019.
Number 5: A new study shows the extent to which financial hardship is impacting seriously ill Medicare beneficiaries.
Number 4: During the FT Global Pharmaceutical and Biotechnology Conference, Celltrion gave a look at its plans for CT-P13.
Number 3: Prescription drug prices are now front and center in the push to make health insurance coverage more affordable to provide to American workers.
Number 2: Price hikes alone accounted for most recent spending growth on biologics, according to research presented at the American College of Rheumatology’s 2019 annual meeting.
Number 1: On Monday, the first biosimilar rituximab began to reach US oncology patients.
Finally, last week, our e-newsletter asked whether you are optimistic that Stephen Hahn, MD, will be proactive about biosimilars if he is confirmed as the next FDA Commissioner.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
